Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9734325 | 0.80 | ALDH1A1 (1.00) | CYP2D6CYP2C19CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL30122631 | 0.79 | MAPK1 (0.75) | ALDH1A1POLBKDM4EHSD17B10MAPK1 | |
| SCHEMBL1682746 | 0.79 | MAPK1 (0.75) | ALDH1A1POLBKDM4EHSD17B10MAPK1 | |
| SCHEMBL1703867 | 0.76 | POLB (0.74) | ALDH1A1MEN1KMT2APOLBHSD17B10 | |
| SCHEMBL1703812 | 0.75 | SMN1; SMN2 (0.49) | CYP2D6CYP2C19CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL3759451 | 0.74 | LMNA (0.65) | CYP2D6CYP2C19CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL4061235 | 0.72 | MEN1 (0.56) | CYP2D6CYP2C19CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL2631381 | 0.72 | MAPK1 (0.74) | ALDH1A1POLBHSD17B10MAPK1ALOX12 | |
| SCHEMBL9734089 | 0.72 | GRM5 (0.50) | CYP2D6CYP2C19CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL2118476 | 0.71 | MAPK1 (0.76) | ALDH1A1MEN1KMT2APOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2441768-A1 | Thienopyrimidinones for treatment of inflammatory disorders and cancers | Eli Lilly & Co. (US) | 2012-04-18 | — | — | EP | disclosed |
| EP-2441768-A1 | Thienopyrimidinones for treatment of inflammatory disorders and cancers | Eli Lilly & Co. (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ICOS CORPORATION | 2010-08-26 | — | — | US | disclosed |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ICOS CORPORATION | 2010-08-26 | — | — | US | disclosed |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ICOS CORPORATION | 2010-08-26 | — | — | US | disclosed |
| EP-2097422-A1 | THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | Eli Lilly & Co. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008064018-A1 | THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ELI LILLY & CO. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064018-A1 | THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ELI LILLY & CO. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | PIK3CA, PIK3CD, PIK3CB | CYP2D6 1315/4885CYP2C19 506/4885CYP1A2 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.